Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Assets (2019 - 2025)

Historic Current Assets for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $2.0 billion.

  • Avidity Biosciences' Current Assets rose 2121.94% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 2121.94%. This contributed to the annual value of $1.5 billion for FY2024, which is 15229.39% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Current Assets is $2.0 billion, which was up 2121.94% from $1.3 billion recorded in Q2 2025.
  • Avidity Biosciences' Current Assets' 5-year high stood at $2.0 billion during Q3 2025, with a 5-year trough of $287.3 million in Q2 2021.
  • Its 5-year average for Current Assets is $827.2 million, with a median of $597.1 million in 2023.
  • Its Current Assets has fluctuated over the past 5 years, first plummeted by 1879.73% in 2021, then surged by 19197.19% in 2024.
  • Quarter analysis of 5 years shows Avidity Biosciences' Current Assets stood at $411.1 million in 2021, then surged by 51.52% to $622.9 million in 2022, then dropped by 1.87% to $611.3 million in 2023, then skyrocketed by 152.29% to $1.5 billion in 2024, then increased by 27.47% to $2.0 billion in 2025.
  • Its Current Assets was $2.0 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.4 billion in Q1 2025.